SCNI News and Press, Scanner Technologies Corp From 02/13/24

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat Halpert as head ...

Scinai Welcomes Liat Halpert as Head of Business Development and Sales PR Newswire JERUSALEM , Feb. 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI ), a biopharmaceutical company focused on developing inflammation and immunology (I&I...

Estimates from the United Nations show that about 363 million individuals worldwide are affected by humanitarian crises driven by the climate crisis, increase conflict and fragility, and broadening inequality. In 2022, more than 108 million individuals were forced to flee their homes due to c...

2024-01-30 16:29:25 ET More on Scinai Immunotherapeutics Scinai Immunotherapeutics to raise $1.7M through exercise of outstanding warrants Seeking Alpha’s Quant Rating on Scinai Immunotherapeutics Read the full article on Seeking Alpha For further deta...

La Jolla Institute for Immunology (LJI) scientists have uncovered a critical T-cell in children’s brains that could help fight pediatric brain tumors. The research team published a study in the journal “ Nature Cancer” outlining how the cancer-killing T cells may already b...

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products, is congratulating its colead scientific research collaborator Professor Dr. Dirk Görlich, w...

Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize PR Newswire JERUSALEM , Jan. 25, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focu...

Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds PR Newswire JERUSALEM , Jan. 4, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused both on...

Scinai Immunotherapeutics CEO Issues Letter to Shareholders PR Newswire JERUSALEM , Jan. 4, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biologica...

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products and provision of boutique CDMO (“CDMO”) services, has entered a d...